nemoci-sympt/LYMFOLOGIE/zmirnujici-faktory-otoku/LYMFOCHIRURGIE/bio-bridge
Incorporated recombinant VEGF-C in nanofibrillar collagen scaffolds (BioBridge™)
- Designed to guide lymphangiogenesis across an area of obstruction
- (Hadamitzky et al., 2016)
Porcine model animals that underwent lymphatic ligation
- BioBridge alone x BioBridge™ with autologous lymph node transplantation
- Three months following surgery BioBridge™
- Treatment increased functional lymphatic regeneration
Rat lymphedema model
- Lymphadenectomy implanted with BioBridge™ with or without autologous ADSCs
- Four months after surgery BioBridge™ (with or without ADSCs)
- Had decreased swelling
- Increased lymphatic collateralization towards other lymph node drainage basins. (Nguyen et al., 2021a)
Following implantation in patients
- Scar release and vascularized lymph node transplantation (VLNT)
- Or lymphovenous anastomosis (LVA) for treatment of secondary lymphedema of the upper or lower extremity (Danielle et al., 2019)
- Qualitatively decreased dermal backflow at the site of device implantation and dynamic uptake of ICG in the newly formed collectors draining into the area where VLNT was performed
Complete or nearly complete edema reduction
- Two patients with mild lower extremity lymphedema treated with BioBridge implantation and LVA
- One patient with a moderate disease of the upper extremity treated with BioBridge™ and VLNT.
Retrospective cohort study of 29 patients
- With stage I-III lymphedema of the upper or lower extremity
- Treated with LVA or VLNT
- With (n = 18 patients)
- Or without (n = 11 patient) BioBridge™ implantation. (Nguyen et al., 2021b)
- At 1-year follow-up
- Significantly decreased edema in patients treated with LVA or VLNT and implanted with BioBridge™
- As compared to patients treated with surgery alone (although the patients treated with LVA or VLNT also showed improvements).
- Lymphatic mapping with ICG quantitatively showed
- More collectors
- Decreased dermal backflow in patients implanted with BioBridge
